Eisai

H3 Biomedicine opens headquarters in Cambridge, Massachusetts

Friday, December 2, 2011 05:10 PM

H3 Biomedicine has opened a new headquarters and 24,000 square feet of state-of-the-art laboratory space in Cambridge, Massachusetts. Over the next year, the company plans to increase its staff to 70 people and further expand into more laboratory space within its building as it continues to pursue its mission to fulfill the promise of personalized cancer medicine.

More... »

Eisai partners with SFJ in new outsourcing model

Friday, September 9, 2011 11:30 AM

Eisai has put the late-stage clinical development, as well as the associated funding, of a candidate compound for thyroid cancer in the hands of SFJ Pharma, wholly subsidiary of a US-based company that specializes in getting innovative drugs to market in Japan, according to PharmaTimes.

More... »

Rejected: Eisai’s Aricept patch

Tuesday, April 26, 2011 01:36 PM

The FDA has rejected Japanese drugmaker Eisai’s patch version of its Alzheimer’s disease drug Aricept (donepezil transdermal system), according to Pharma Times.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »

Eisai expands into Brazil

Friday, April 8, 2011 10:24 AM

Eisai, based in Japan, is moving into Latin America and is opening a subsidiary in Brazil, according to Pharma Times.

More... »

Eisai's eribulin gets EU approval for breast cancer

Tuesday, March 29, 2011 12:44 PM

Regulators in Europe have approved Eisai’s marine-derived breast cancer drug Halaven.

More... »

Epizyme collaborates with Eisai

Thursday, March 10, 2011 01:45 PM

Just weeks after GlaxoSmithKline committed up to $650 million in its epigenetics pact with Cambridge, Mass.-based Epizyme, Japan's Eisai has joined the promising discovery platform with a $206 million collaboration of its own, according to Fierce Biotech.

More... »

Eisai cuts to hit U.S. workforce

Wednesday, March 9, 2011 10:10 AM

More details are being released about Japanese drugmaker Eisai’s previously announced five years of job cuts totaling 900 positions. Eisai intends to slice 20% of its work force, or 600 jobs, in the U.S., by April 1.

More... »

Eisai reports new data on Halaven

Tuesday, March 8, 2011 10:24 AM

Eisai, based in Japan, reported new data confirming its marine-derived drug Halaven improves overall survival in women with late-stage breast cancer. 

More... »

Eisai to cut 900 jobs

Thursday, March 3, 2011 03:15 PM

As a result of losing patent protection of its top-selling Alzheimer's disease treatment Aricept, Eisai plans to cut 900 jobs over the next five years, according to Fierce Pharma. The jobs will come from U.S., Japanese and European operations.

More... »